Get the Stockscreener App
252.72
0.10%
-0.0196
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $252.72, with a volume of 208.53K.
It is down -0.10% in the last 24 hours and up +12.00% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$252.74
Open:
$251.2
24h Volume:
208.53K
Relative Volume:
0.03
Market Cap:
$446.10B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
124.65
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
-3.29%
1M Performance:
+12.00%
6M Performance:
+14.72%
1Y Performance:
+32.45%
1-Day Range:
$250.55
$252.97
1-Week Range:
$250.55
$260.92
52-Week Range:
$184.63
$261.63
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
252.49 | 446.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,217.32 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
262.58 | 634.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
125.40 | 311.17B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.18 | 296.08B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
ABBV Maintained by JP Morgan -- Price Target Raised to $280 - GuruFocus
ABBV Leads Its Peer Group. You Pay For That - Trefis
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? - The Motley Fool
AbbVie stock trades steadily as investors weigh immunology and oncology pipeline - Ad-hoc-news.de
AbbVie Stock Traded Its Old Story for New Growth. Here Is The Price. - Trefis
AbbVie (NYSE:ABBV) Dividend Streak Gains Fresh Market Focus - Kalkine Media
AbbVie accused of hiding painful lump risk from Juvederm patients in new lawsuit - Claim Depot
AbbVie Stock Traded Its Old Story For New Growth. Here Is The Price. - Trefis
AbbVie Earnings Preview: What to Expect - Barchart.com
AbbVie Inc. outlines long-term growth drivers as a major biopharma player - AD HOC NEWS
More Than 2.5 Million Generic Prednisolone Acetate Eye Drops Recalled - Optometry Advisor
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years - Barchart.com
AbbVie (NYSE:ABBV) Turns Rotation Into A Growth Story - Kalkine Media
AbbVie (ABBV) Expands Tepkinly Label for Follicular Lymphoma Tre - GuruFocus
AbbVie, Genmab win EU label expansion for Tepkinly (ABBV:NYSE) - Seeking Alpha
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List) - Yahoo Finance
Global markets live: Broadcom, Meta, Walmart, Intel, AbbVie… - marketscreener.com
EC approves AbbVie’s Tepkinly combination for follicular lymphoma - Pharmaceutical Business review -
AbbVie Inc. outlines long-term growth strategy as a major biopharma player - AD HOC NEWS
AbbVie (ABBV) Lowers Q2 Earnings Guidance Amid IPR&D Expenses - GuruFocus
AbbVie (ABBV) Adjusted EPS Guidance for Q2 Signals Slight Underp - GuruFocus
AbbVie revises guidance; expects Q2 EPS to include unfavorable impact of $0.17 - MSN
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie (ABBV) Receives EU Approval for TEPKINLY in Follicular Ly - GuruFocus
AbbVie Announces TEPKINLY® in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - Investing News Network
Abbvie Says Tepkinly In Combination With Lenalidomide And Rituximab Approved By European Commission - TradingView
AbbVie's Post-Humira Triumph: Skyrizi and Rinvoq Drive Sector-Leading Growth - Kavout | AI
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - Yahoo Finance UK
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results? - The Globe and Mail
HSBC Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $300 - Moomoo
ABBV Maintained by Cantor Fitzgerald -- Price Target Raised to $265 - GuruFocus
The Zacks Analyst Blog Highlights Applied Materials, Mastercard, AbbVie, INNOVATE and BranchOut - Yahoo Finance
AbbVie Inc. (ABBV) Stock Analysis: Navigating a High Dividend Yield Amid Market Dynamics - DirectorsTalk Interviews
CBOE Vest S&P 500 Dividend Aristocrats Target Income ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
ABBVAbbvie Inc Latest SEC Filings - Finviz
The Osterweis Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
ABBV News | ABBVIE INC (NYSE:ABBV) - ChartMill
AbbVie to buy Apogee Therapeutics (APGE) for $135.11 per share — significant premium - Stock Titan
AbbVie Inc (ABBV) Shares Surge 4.0% -- What GF Score of 82 Tells Investors - GuruFocus
AbbVie faces federal probe over drug trials in China - Crain's Chicago Business
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Top Research Reports for Applied Materials, Mastercard & AbbVie - Zacks Investment Research
AbbVie Inc Stock (ABBV) Moved Up by 3.44% on Jul 2: Drivers Behind the Movement - TradingKey
AbbVie (ABBV) Reaches 52-Week High Amid Proposed Changes to Drug Pricing Program - GuruFocus
AbbVie, Other Healthcare Stocks Rise as Trump Administration Reportedly Targets Hospital Drug Markups - Moomoo
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now? - TradingView
Stronger Bet Than AbbVie Stock: INCY Delivers More - Trefis
AbbVie Inc.: Target Price Consensus and Analysts Recommendations | ABBV | US00287Y1091 - marketscreener.com
AbbVie: Apogee Deal Just Widened An Already Dominant Moat - Seeking Alpha
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):